USD 0.31
(3.12%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 412 Thousand USD | 380.27% |
2022 | -147 Thousand USD | 90.44% |
2021 | -1.53 Million USD | -42.8% |
2020 | -1.07 Million USD | 34.77% |
2019 | -1.65 Million USD | -180.5% |
2018 | 2.05 Million USD | 20.29% |
2017 | 1.7 Million USD | -39.92% |
2016 | 2.83 Million USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | 77 Thousand USD | -36.36% |
2024 Q2 | -438 Thousand USD | 0.0% |
2023 Q2 | 89 Thousand USD | 18.67% |
2023 Q1 | 75 Thousand USD | 151.02% |
2023 FY | 412 Thousand USD | 380.27% |
2023 Q4 | 121 Thousand USD | -4.72% |
2023 Q3 | 127 Thousand USD | 42.7% |
2022 Q1 | -86 Thousand USD | 74.85% |
2022 FY | -147 Thousand USD | 90.44% |
2022 Q4 | -147 Thousand USD | -98.65% |
2022 Q3 | -74 Thousand USD | -21.31% |
2022 Q2 | -61 Thousand USD | 29.07% |
2021 Q2 | -483 Thousand USD | -89.41% |
2021 Q4 | -342 Thousand USD | -41.91% |
2021 FY | -1.53 Million USD | -42.8% |
2021 Q3 | -241 Thousand USD | 50.1% |
2021 Q1 | -255 Thousand USD | -165.63% |
2020 FY | -1.07 Million USD | 34.77% |
2020 Q2 | -267 Thousand USD | -27.14% |
2020 Q4 | -96 Thousand USD | 80.95% |
2020 Q3 | -504 Thousand USD | -88.76% |
2020 Q1 | -210 Thousand USD | 41.67% |
2019 Q3 | -517 Thousand USD | 10.86% |
2019 Q2 | -580 Thousand USD | -198.97% |
2019 Q1 | -194 Thousand USD | -124.62% |
2019 FY | -1.65 Million USD | -180.5% |
2019 Q4 | -360 Thousand USD | 30.37% |
2018 Q2 | 246 Thousand USD | 5.58% |
2018 FY | 2.05 Million USD | 20.29% |
2018 Q4 | 788 Thousand USD | 0.51% |
2018 Q1 | 233 Thousand USD | -16.49% |
2018 Q3 | 784 Thousand USD | 218.7% |
2017 Q4 | 279 Thousand USD | -53.34% |
2017 Q2 | 367 Thousand USD | -20.73% |
2017 Q1 | 463 Thousand USD | 0.0% |
2017 Q3 | 598 Thousand USD | 62.94% |
2017 FY | 1.7 Million USD | -39.92% |
2016 FY | 2.83 Million USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Perspective Therapeutics, Inc. | 1.63 Million USD | 74.786% |
Electromed, Inc. | 41.72 Million USD | 99.013% |
Senseonics Holdings, Inc. | 3.09 Million USD | 86.671% |
Xtant Medical Holdings, Inc. | 55.46 Million USD | 99.257% |